text_1: MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.
text_2: Furthermore, clinical trials with PI3K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.